Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
Clinical Gastroenterology and Hepatology · 2026-05
DOI: 10.1016/j.cgh.2026.05.010 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Jiayin Yao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Cente…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Health Promotion Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND & AIMS: Current advanced therapies for ulcerative colitis face an "efficacy ceiling," with endoscopic remission rates rarely exceeding 30%. We evaluated whether combination therapy-8-week induction with upadacitinib and vedolizumab followed by vedolizumab monotherapy-would be superior to standard vedolizumab monotherapy. METHODS: In this prospective, multicenter, randomized, open-label, superiority trial at 8 centers in China, adults with moderate-to-severe ulcerative colitis (modified Mayo score 4-9, endoscopic subscore ≥2) were randomized 1:2 to combination therapy (vedolizumab 300 mg intravenously at weeks 0, 2, and 6 plus upadacitinib 45 mg daily for 8 weeks) or vedolizumab monotherapy. The primary endpoint was endoscopic remission (Mayo endoscopic subscore of 0) at week 8, assessed by blinded central readers. RESULTS: Of 120 randomized patients, 113 comprised the modified intention-to-treat population (40 combination, 73 monotherapy). Endoscopic remission at week 8 was achieved by 37.5% vs 15.1% (absolute risk difference, 22.4 percentage points; 95% confidence interval, 5.3-39.5; adjusted odds ratio, 3.34; 95% confidence interval, 1.34-8.58; P = .010). Clinical remission (65.0% vs 35.6%; P = .002) and histologic-endoscopic mucosal improvement (40.0% vs 13.7%; P = .004) were significantly higher with combination therapy. Adverse event rates were comparable (7.5% vs 6.8%), with no serious adverse events. CONCLUSIONS: In this open-label trial, combined upadacitinib and vedolizumab induction was superior to vedolizumab monotherapy for achieving endoscopic and clinical remission at week 8 in patients with moderate-to-severe ulcerative colitis. Although these findings should be interpreted with caution, given the early trial termination and open-label design, they provide the first randomized evidence supporting a short-term combination biologic and small-molecule induction strategy. CLINICALTRIALS: gov, Number: NCT06095596.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Center for Digestive Diseases, Guangzhou, Guangdong, China.
- Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hepato-Gastroenterology, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Gastroenterology, Huizhou First People's Hospital, Huizhou City, Guangdong, China.
- Department of Gastroenterology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, Guangdong, China.
Förderung
- China Health Promotion Foundation
- National Natural Science Foundation of China
Zitieren
APA
Yao, J., Wu, H., Wu, L., Yu, Q., Cao, X., Xie, T., Zhong, X., Chen, H., Wu, J., Liu, X., Shi, L., Zhang, M., Peng, X., Deng, J., Wang, W., Liu, T., Su, T., Yang, H., Xia, D., & Zhi, M. (2026). Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.05.010
Vancouver
Yao J, Wu H, Wu L, Yu Q, Cao X, Xie T, et al. Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.05.010
BibTeX
@article{Yao2026,
author = {Yao, Jiayin and Wu, Hongzhen and Wu, Luying and Yu, Qiao and Cao, Xiaocang and Xie, Tingting and Zhong, Xuanfang and Chen, Huangwei and Wu, Ji and Liu, Xiaoyu and Shi, Lishuo and Zhang, Min and Peng, Xiang and Deng, Jun and Wang, Wei and Liu, Tao and Su, Tao and Yang, Hui and Xia, Dengning and Zhi, Min},
title = {Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.05.010}
}
EUVIMED